Caulerpin as a potential antiviral drug against herpes simplex virus type 1

AUTOR(ES)

Macedo, Nathália Regina Porto Vieira, Ribeiro, Michele S., Villaça, Roberto C., Ferreira, Wilton, Pinto, Ana Maria, Teixeira, Valéria L., Cirne-Santos, Claudio, Paixão, Izabel C. N. P., Giongo, Viveca

FONTE

Revista Brasileira de Farmacognosia

DATA DE PUBLICAÇÃO

29/05/2012

RESUMO

About 80% of the human adult population is infected with HSV-1. Although there are many anti-HSV-1 drugs available (acyclovir, ganciclovir, valaciclovir, foscarnet), their continuous use promotes the selection of resistant strains, mainly in ACV patients. In addition to resistance, the drugs also have toxicity, particularly when administration is prolonged. The study of new molecules isolated from green algae with potential antiviral activity represents a good opportunity for the development of antiviral drugs. Caulerpin, the major product from the marine algae Caulerpa Lamouroux (Caulerpales), is known for its biological activities such as antioxidant, antifungal, acetylcholinesterase inhibitor (AChE) and antibacterial activity. In this work, we show that caulerpin could be an alternative to acyclovir as an anti-HSV-1 drug that inhibits the alpha and beta phases of the replication cycle.

Documentos Relacionados

• Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds.
• Antiviral drug sensitivity in ocular herpes simplex virus infection.
• Antiviral Activity of a Selective Ribonucleotide Reductase Inhibitor against Acyclovir-Resistant Herpes Simplex Virus Type 1 In Vivo
• Antiviral activity of antilipidemic compounds on herpes simplex virus type 1.
• Antiviral activities of Radix Isatidis polysaccharide against type II herpes simplex virus in vitro